First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer

BACKGROUND: Nivolumab has been associated with longer overall survival than docetaxel among patients with previously treated non-small-cell lung cancer (NSCLC). In an open-label phase 3 trial, we compared first-line nivolumab with chemotherapy in patients with programmed death ligand 1 (PD-Ll)-posit...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:N Engl J Med
Hlavní autoři: Carbone, D.P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M.M., Ciuleanu, T.-E., Badin, F., Ready, N., Hiltermann, T.J.N., Nair, S., Juergens, R., Peters, S., Minenza, E., Wrangle, J.M., Rodriguez-Abreu, D., Borghaei, H., Blumenschein, G.R., Villaruz, L.C., Havel, L., Krejci, J., Jaime, J. Corral, Chang, H., Geese, W.J., Bhagavatheeswaran, P., Chen, A.C., Socinski, M.A.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2017
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6487310/
https://ncbi.nlm.nih.gov/pubmed/28636851
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1613493
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky